{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-23-000003","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.149257+00:00","generated_at":"2026-06-20T17:59:17.498944+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Entrada selects clinical candidate ENTR-601-45 for DMD exon 45 skipping; IND in H2 2024","bullets":["ENTR-601-45 is an EEV-conjugated PMO targeting Duchenne patients amenable to exon 45 skipping.","In vivo data showed >90% exon skipping in skeletal muscle of hDMD mouse model after single IV dose.","More than 1,300 patients in US and Europe are exon 45 skipping amenable, per Entrada.","Company plans to submit IND application in second half of 2024.","Additional data expected at MDA Clinical & Scientific Conference in March 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-23-000003","json":"https://secwatch.observer/filing/0001689375-23-000003.json","markdown":"https://secwatch.observer/filing/0001689375-23-000003.md","text":"https://secwatch.observer/filing/0001689375-23-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000003/0001689375-23-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000003/trda-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:59:17.498944+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}